12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cx601: Phase IIa data

Data from 22 evaluable patients in a Spanish Phase IIa trial showed that Cx601 was safe with only 5 patients experiencing adverse events considered potentially related to treatment. Additionally, Cx601-treated...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >